Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Next Generation Immunotherapies Market Expected to Grow Between 2025 And 2029?
The market size for next-generation immunotherapies has seen significant expansion in recent years, with projections indicating a growth from $133.81 billion in 2024, to $150.12 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.2%. Factors contributing to this increase during the historic period include an amplified prevalence of oncology conditions, heightened investment in research and development, increased government initiatives, greater government spending on healthcare, and broader indications.
The market size of next-generation immunotherapies is predicted to experience swift expansion in the upcoming years. The market is set to rise to$235.85 billion” by 2029, indicating a compound annual growth rate (CAGR) of 12.0%. The surge in this predicted period can be attributed to factors like the growing prevalence of cancer, increased healthcare spending, the widespread adoption of chimeric antigen receptor (CAR) T- cell therapy, the increasing chronic disease burden, and an escalation in research focused on next-generation drugs. Major trends during this forecast period include the shift towards combination therapies, technological breakthroughs, innovative therapeutic strategies, progress in personalized medicine, and advancements in regulatory support.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Next Generation Immunotherapies Market?
The rise in cancer cases is anticipated to spur the expansion of the market for next-generation immunotherapies. Cancer, defined by abnormal cell growth and proliferation in the body, is increasingly common due to aging populations, changes in lifestyle, environmental influences, and enhanced detection techniques. Next-generation immunotherapies present sophisticated, specialized treatments that augment the body’s immune response to cancer, ensuring more effective, long-lasting, and tailored care. For example, the National Cancer Institute (NCI), a governmental agency in the US, disclosed in May 2024 that almost 20 million new cancer cases and 9.7 million cancer-related fatalities were recorded worldwide in 2022. They further predict that by 2040, there will be 29.9 million new cancer cases and 15.3 million cancer-linked deaths. Hence, the escalating prevalence of cancer is fueling the advancement of the next-generation immunotherapies market.
Which Primary Segments of the Next Generation Immunotherapies Market Are Driving Growth and Industry Transformations?
The next generation immunotherapiesmarket covered in this report is segmented –
1) By Drug Class: Monoclonal Antibodies; Antibody-Drug Conjugates – ADC’s; Angiotensin-Converting Enzyme (ACE) Inhibitors; Immune Checkpoint Inhibitors
2) By Route Of Administration: Intravenous; Parenteral; Intratumoral; Subcutaneous; Oral
3) By Distribution Channel: Hospital Pharmacies; Clinical Pharmacies; Other Distribution channels
Subsegments:
1) By Monoclonal Antibodies: Anti-PD-1 Antibodies; Anti-PD-L1 Antibodies; Anti-CTLA-4 Antibodies; Anti-CD20 Antibodies; Other Monoclonal Antibodies
2) By Antibody-Drug Conjugates (ADC’s): HER2-targeted ADCs; CD30-targeted ADCs; CD19-targeted ADCs; Other ADCs
3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy; ACE Inhibitors For Other Indications
4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors; CTLA-4 Inhibitors; Other Immune Checkpoint Inhibitors
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21231&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Next Generation Immunotherapies Market?# Market?
North America was the largest region in the next-generation immunotherapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Next Generation Immunotherapies Market?
Major firms involved in the next-generation immunotherapies market are directing their efforts towards the development of groundbreaking therapies, encapsulating CAR T-cell therapy to combat cancers, autoimmune disorders, and infectious diseases. In this specific type of immunotherapy, a patient’s T cells (an immune cell category) are genetically tweaked to carry chimeric antigen receptors (CARs). For illustration, in January 2025, Immuneel Therapeutics Private Limited, an Indian cell and gene therapy pioneer, unveiled Qartemi, marking India’s first CAR T-cell therapy. This treatment targets adult B-cell non-Hodgkin lymphoma and involves the genetic alteration of a patient’s immune cells to specifically target and annihilate cancer cells, thereby providing a highly custom and effective treatment alternative. This therapy represents a beacon of hope for patients who haven’t had success with traditional treatment techniques, backed by the added benefit of being cost-effective compared to similar international options.
View the full report here:
What Parameters Are Used to Define the Next Generation Immunotherapies Market?
Next-generation immunotherapies refer to advanced treatments designed to enhance the body’s immune system to fight diseases, particularly cancer, with improved precision, efficacy, and safety. These therapies go beyond traditional immune-based treatments by leveraging cutting-edge technologies and aim to overcome earlier immunotherapies’ limitations, reduce side effects, and offer long-lasting immune responses.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21231
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
